Lizhu Lin - Concepedia

Author

Lizhu Lin

First Affiliated Hospital of Guangzhou University of Chinese Medicine ORCID

Also Known As

L. Lin, L.L. Lin, LI-CHING LIN, Lei-Po Lin, Lester Wei Lin Ong, Li-Zhu Lin, Li-zhu Lin, LiZhu Lin, Lin Li-Zhu, Lin, L.

108

Publications

2.2K

Citations

H-Index

Concepts

All Affiliations

First Affiliated Hospital of Guangzhou University of Chinese Medicine Guangzhou University of Chinese Medicine Sun Yat-sen University Guangzhou Medical University Nanchang University

About

Lizhu Lin is an author at First Affiliated Hospital of Guangzhou University of Chinese Medicine specializing in medicine, oncology, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	16	1.2K
2	Health Sciences	5	5	570
3	Natural Sciences	1	1	113
4	Allergy	1	1	232
5	Biochemistry	1	1	113

Lizhu Lin

Publications

1.9K

Citations

H-Index

Page 1

	Year	Citations
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial Caicun Zhou, Gongyan Chen, Yunchao Huang, The Lancet Respiratory Medicine OncologyClinical TrialsChemotherapy-naive PatientsImmune Checkpoint InhibitorPharmacotherapy	2020	488
Interleukin-1 alpha induces the accumulation of cytosolic phospholipase A2 and the release of prostaglandin E2 in human fibroblasts. Lizhu Lin, Alice Lin, David L. DeWitt Journal of Biological Chemistry Inflammatory Lung DiseaseImmunologyPathologyCell DeathCytosolic Phospholipase A2	1992	232
Macrophage colony stimulating factor activates phosphatidylcholine hydrolysis by cytoplasmic phospholipase A2. Takashi Nakamura, Lizhu Lin, Surender Kharbanda, The EMBO Journal Proteinlipid InteractionMacrophage ColonySignal TransductionBiochemistryNatural Sciences	1992	113
The dietary flavone luteolin epigenetically activates the Nrf2 pathway and blocks cell transformation in human colorectal cancer HCT116 cells Qian Zuo, Renyi Wu, Xi Xiao, Journal of Cellular Biochemistry	2018	94
Camrelizumab Plus Carboplatin and Pemetrexed as First-Line Treatment for Advanced Nonsquamous NSCLC: Extended Follow-Up of CameL Phase 3 Trial Caicun Zhou, Gongyan Chen, Yunchao Huang, Journal of Thoracic Oncology Advanced Nonsquamous NsclcOncologyCamrelizumab Plus CarboplatinMedicineClinical Trials	2023	65
Rosmarinic acid reverses non‐small cell lung cancer cisplatin resistance by activating the MAPK signaling pathway Xiaozhong Liao, Ying Gao, Lingling Sun, Phytotherapy Research OncologyNsclc Cell ProliferationTumor MicroenvironmentMedicineRosmarinic Acid	2020	64
Tanshinone IIA combined with cisplatin synergistically inhibits non‐small‐cell lung cancer in vitro and in vivo via down‐regulating the phosphatidylinositol 3‐kinase/Akt signalling pathway Xiaozhong Liao, Ying Gao, Sheng Huang, Phytotherapy Research	2019	63
Cordycepin Reverses Cisplatin Resistance in Non-small Cell Lung Cancer by Activating AMPK and Inhibiting AKT Signaling Pathway Xiaozhong Liao, Ying Gao, Hongwei Zhao, Frontiers in Cell and Developmental Biology	2021	52
A pilot randomized controlled trial of acupuncture at the Si Guan Xue for cancer pain To-Yi Lam, Liming Lu, W.M. Ling, BMC Complementary and Alternative Medicine	2017	48
RETRACTED ARTICLE: Tiliroside as a CAXII inhibitor suppresses liver cancer development and modulates E2Fs/Caspase-3 axis Rui Han, Hongxing Yang, Lingeng Lu, Scientific Reports	2021	41

Page 1